NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
02/14/24, 12:09 PM
Location
cambridgeMoney raised
$123 million
Industry
biotechnology
Round Type
series b
Investors
Wtt Investment Ltd, Arkin Bio Capital, Gordon Freeman, Ph D, Binney Street Capital, Sixty Degree Capital, Invus, Sanofi Ventures, Leaps By Bayer, Mpm Bio Impact, Catalio Capital Management
NextPoint Therapeutics announced the closing of a $42.5M Extension to its Series B financing round, resulting in a total of $122.5M raised. The funds will be used to advance the company’s immuno-oncology clinical programs and propel the development of additional therapeutic modalities targeting the novel HHLA2 tumor antigen.
Company Info
Location
238 main street
cambridge, maryland, united states
Additional Info
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.